Stay updated on Nivolumab Combo in Relapsed/Refractory HL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page.

Latest updates to the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page
- ChecktodayChange DetectedRevision updated from v3.4.3 to v3.5.0; a maintenance update with no changes to study details or criteria.SummaryDifference0.0%

- Check7 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedFooter updated to Revision: v3.4.2; the funding-lapse notice and the older Revision: v3.4.1 text were removed.SummaryDifference0.3%

- Check43 days agoChange DetectedAdded a system-wide notice about potential data delays due to a lapse in government funding and updated operating status guidance, with references to cc.nih.gov and opm.gov. Updated the page revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check50 days agoChange DetectedAdded a glossary display and updated QC-related metadata to show 2025-10-20 Last Update Submitted that Met QC Criteria and Last Update Posted, along with No FEAR Act Data and Revision: v3.4.0. Removed older QC metadata (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data) and the prior Revision: v3.3.4.SummaryDifference0.3%

- Check64 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No substantive changes to study content, layout, or links are evident.SummaryDifference0.0%

Stay in the know with updates to Nivolumab Combo in Relapsed/Refractory HL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page.